Nasdaq · Biotech stocks database
TLSA (Tiziana Life Sciences Ltd. Common Shares) stock: $0.91, $115.2M market cap, $4.0M cash, $111.5M EV, $116.4M fully diluted market cap. Next expected readout: Apr-27. Lead program: Foralumab Nasal (Multiple System Atrophy), Phase 2. Data from Fully Diluted's biotech stocks database.
| Cash | $4.0M |
|---|---|
| Debt | $0.3M |
| Net cash | $3.7M |
| Enterprise value | $111.5M |
| Basic shares | 127.7M shares |
| Fully diluted shares | 127.9M shares |
| Fully diluted market cap | $116.4M |
| Cash per share | $0.03 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading TLSA daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Oct 13 - Nov 24 | Foralumab | Phase 2 | Secondary Progressive Multiple Sclerosis | — |
| May 13 - Jun 24 | Foralumab Nasal | Phase 2 | Multiple System Atrophy | — |
| Aug 12 - Sep 23 | Foralumab Nasal | Phase 2 | ALS (Amyotrophic Lateral Sclerosis); ALS - Amyotrophic Lateral Sclerosis; ALS | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.